Details of Disease

General Information of Disease (ID: DISU4KOQ)

Disease Name Graves disease
Synonyms Graves' hyperthyroidism; Basedow's disease; parry disease; Basedow disease; Graves' disease; grave's disease; exophthalmic goitre; exophthalmic goiter; Graves disease
Disease Class 5A02: Thyrotoxicosis
Definition
Graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism).It is caused by an abnormal immune system response that causes the thyroid gland to produce too much thyroid hormones. Graves disease is the most common cause of hyperthyroidism andoccurs mostoften in women over age 20. However, the disorder may occur at any age and may affect males as well.Treatmentmayinclude radioiodine therapy, antithyroid drugs, and/or thyroid surgery.
Disease Hierarchy
DISJJUUM: Toxic diffuse goiter
DISLCGI6: Goiter
DISIHC6A: Autoimmune thyroid disease
DISU4KOQ: Graves disease
ICD Code
ICD-11
ICD-11: 5A02.0
ICD-10
ICD-10: E05.0, H06.2
Expand ICD-11
'5A02.0
Expand ICD-10
'E05.0; 'H06.2
Disease Identifiers
MONDO ID
MONDO_0005364
MESH ID
D006111
UMLS CUI
C0018213
MedGen ID
6677
HPO ID
HP:0100647
SNOMED CT ID
353295004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Carbimazole DMULAI4 Approved Small molecular drug [1]
Ipodate DM72ZYN Approved Small molecular drug [2]
Teprotumumab DM4L59B Approved NA [3]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CFZ533 DM1TWIE Phase 2 NA [4]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ATX-GD DMRM9M5 Investigative NA [5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 64 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
BLK TTNDSC3 Limited Genetic Variation [6]
HLA-B TTGS10J Limited Biomarker [7]
IKZF3 TTCZVFZ Limited Genetic Variation [8]
ITPR3 TTH1769 Limited Genetic Variation [9]
SLAMF6 TTSIYJ6 Limited Genetic Variation [10]
SLC12A3 TTP362L Limited Genetic Variation [11]
CD160 TTOFEAS moderate Biomarker [12]
CD83 TTT9MRQ moderate Altered Expression [13]
IL18RAP TTZUJVE moderate Genetic Variation [14]
IL1RL1 TT4GZA4 moderate Genetic Variation [14]
TBX21 TTNF9PH moderate Genetic Variation [15]
ADRB1 TTR6W5O Strong Biomarker [16]
CD19 TTW640A Strong Biomarker [17]
CD28 TTQ13FT Strong Biomarker [18]
CD34 TTZAVYN Strong Altered Expression [19]
CD86 TT53XHB Strong Altered Expression [20]
CXCL9 TTWE5PB Strong Biomarker [21]
CXCR5 TTIW59R Strong Biomarker [22]
CYP21A2 TTP4GLG Strong Genetic Variation [9]
DIO1 TTU3X26 Strong Altered Expression [23]
DPYSL2 TTZCW3T Strong Genetic Variation [24]
FASLG TTO7014 Strong Altered Expression [25]
FCER2 TTCH6MU Strong Biomarker [26]
FKBP1A TTMW94E Strong Biomarker [27]
GAD1 TTKGEP3 Strong Biomarker [28]
GAD2 TT7UY6K Strong Biomarker [29]
GNAO1 TTAXD8Z Strong Biomarker [30]
GPR174 TTYUB4M Strong Genetic Variation [31]
HLA-DQB2 TTL7VOU Strong Biomarker [30]
ICA1 TTMX06B Strong Biomarker [32]
ICOS TTE5VP6 Strong Altered Expression [33]
ICOSLG TTB9Z8R Strong Altered Expression [34]
IL16 TTW4R0B Strong Genetic Variation [35]
IL17A TTG0MT6 Strong Altered Expression [36]
IL17F TT2B6PS Strong Genetic Variation [37]
IL21 TT9QEJ6 Strong Biomarker [36]
IL21R TTZO9B0 Strong Biomarker [38]
IL23A TTC1GLB Strong Biomarker [39]
IL23R TT6H4QR Strong Genetic Variation [40]
IL2RA TT10Y9E Strong Biomarker [41]
IL37 TTQTX98 Strong Altered Expression [42]
ITGAE TTH0Z37 Strong Genetic Variation [43]
KCNJ2 TTH7UO3 Strong Genetic Variation [44]
KIR3DL2 TTQH3N0 Strong Biomarker [45]
KLRC1 TTC4IMS Strong Altered Expression [46]
LAIR1 TTSI7A8 Strong Biomarker [47]
LTA TTP73TM Strong Biomarker [48]
LTB TTHQ6US Strong Genetic Variation [49]
MOG TTQAFX5 Strong Genetic Variation [9]
MTNR1A TT0WAIE Strong Biomarker [50]
PDZK1 TTDTBLM Strong Biomarker [51]
POLB TTA0XPV Strong Altered Expression [52]
PPP5C TTTW7FJ Strong Biomarker [53]
PPT1 TTSQC14 Strong Biomarker [53]
QPCT TTJ7YTV Strong Genetic Variation [54]
SELL TT2IYXF Strong Genetic Variation [55]
SLC26A4 TT7X02I Strong Altered Expression [56]
SLC30A8 TTXIGT7 Strong Biomarker [57]
TLR6 TTWRI8V Strong Genetic Variation [58]
TLR7 TTRJ1K4 Strong Genetic Variation [59]
TNFRSF25 TTDV6BQ Strong Genetic Variation [60]
TNFSF13B TTWMIDN Strong Genetic Variation [61]
TRH TT2Z39D Strong Biomarker [62]
CXCL10 TTQOVYA Definitive Biomarker [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 64 DTT(s)
This Disease Is Related to 4 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCC6 DT582KR Limited Biomarker [63]
SLC25A27 DT0HW5C Strong Genetic Variation [64]
SLC26A3 DTN1FMD Strong Altered Expression [65]
SLC30A10 DTYBI73 Strong Biomarker [57]
------------------------------------------------------------------------------------
This Disease Is Related to 8 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ABO DESIA7R Limited Genetic Variation [10]
CYP27B1 DE3FYEM Strong Genetic Variation [66]
CYP2R1 DEBIHM3 Strong Genetic Variation [67]
MMEL1 DEYCUQ2 Strong Genetic Variation [68]
MT1A DE5ME8A Strong Biomarker [50]
UGDH DE48Q2Z Strong Altered Expression [69]
WARS1 DEPVE0M Definitive Altered Expression [70]
WARS2 DEPTKBQ Definitive Altered Expression [70]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
This Disease Is Related to 147 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AGO1 OTD3R434 Limited Altered Expression [71]
BACH2 OT17GS18 Limited Genetic Variation [72]
C1QTNF6 OT57EPQC Limited Genetic Variation [73]
FCRL3 OTIFXFWL Limited Genetic Variation [74]
HCP5 OTV0YRI8 Limited Genetic Variation [75]
IRF7 OTC1A2PQ Limited Genetic Variation [76]
MAGI2 OTXDDKZS Limited Genetic Variation [77]
RAC2 OTAOHFNH Limited Genetic Variation [73]
TAP2 OTWSYFI7 Limited Genetic Variation [78]
DIAPH2 OTBEYFEZ Disputed Genetic Variation [79]
NOX3 OT0FFJH8 Disputed Genetic Variation [80]
POF1B OTFWNK8G Disputed Genetic Variation [79]
ARID5B OTUQ4CQY moderate Genetic Variation [81]
B3GNT2 OTE69HV8 moderate Genetic Variation [82]
BANK1 OTXAAA11 moderate Genetic Variation [83]
DOCK11 OTFSTN6A moderate Genetic Variation [84]
FCRL2 OT0RLDOD moderate Biomarker [85]
FCRL4 OT3DVTRV moderate Altered Expression [85]
FOXD3 OTXYV6GO moderate Altered Expression [86]
GC OTWS63BY moderate Genetic Variation [67]
LST1 OTUVG424 moderate Genetic Variation [87]
NDUFB2 OT4717TF moderate Biomarker [88]
RNASET2 OTWY64L7 moderate Genetic Variation [31]
SSB OTCCTPBR moderate Biomarker [89]
SUMO4 OT9B447E moderate Genetic Variation [90]
AAMDC OT4HGATD Strong Genetic Variation [91]
ABCF1 OT6Q079J Strong Genetic Variation [92]
AIRE OTA7G1Y1 Strong Genetic Variation [93]
ALG1 OTVXPA9E Strong Biomarker [50]
ANGPTL8 OTQFINCD Strong Biomarker [94]
ANXA3 OTDD8OI7 Strong Biomarker [95]
BTG2 OTZF6K1H Strong Genetic Variation [96]
BTNL2 OTTTEMZA Strong Genetic Variation [97]
C2 OTHMF4YM Strong Biomarker [98]
C4A OTXMOYXU Strong Genetic Variation [99]
CCDC6 OTXRQDYG Strong Biomarker [100]
CCDC88A OT3SSYYC Strong Genetic Variation [101]
CCHCR1 OT22C116 Strong Genetic Variation [9]
CD226 OT4UG0KB Strong Genetic Variation [102]
CDSN OTQW4HV6 Strong Genetic Variation [9]
CEP128 OT922YCJ Strong Biomarker [103]
CETN1 OTGQ8JOZ Strong Biomarker [104]
CLTA OTLHOXMQ Strong Genetic Variation [105]
DBP OTE0W7LN Strong Genetic Variation [106]
DCHS2 OTGZJ6KS Strong Genetic Variation [91]
DCT OTYVNTBG Strong Biomarker [107]
DDX39B OTEVCFVU Strong Genetic Variation [9]
DEGS1 OT4WXPKW Strong Biomarker [108]
DIO2 OTGPNSLH Strong Biomarker [109]
DNTT OTFSEF12 Strong Biomarker [110]
DROSHA OTCE68KZ Strong Genetic Variation [111]
DUOX1 OTQ2AEW0 Strong Biomarker [112]
EARS2 OTNCJKY7 Strong Biomarker [113]
ECD OT3L3PCU Strong Biomarker [114]
EFS OT06O7XL Strong Genetic Variation [115]
EMD OTR8ZANE Strong Biomarker [116]
FCGR2C OTNLMNYB Strong Altered Expression [117]
FCRL1 OTXOYT29 Strong Altered Expression [85]
FCRLA OT6MK4M1 Strong Genetic Variation [118]
FLNB OTPCOYL6 Strong Biomarker [119]
FLVCR1 OT9XCFOC Strong Biomarker [120]
FOXE1 OT5IR5IT Strong Biomarker [121]
FUT2 OTLXM6WI Strong Genetic Variation [122]
GDF1 OTZ1VRBH Strong Biomarker [123]
GNL1 OTWTVIVM Strong Biomarker [92]
GTF2H4 OTPD1DIU Strong Altered Expression [124]
GYPB OTESHUIX Strong Biomarker [125]
GYPE OTBHAG6A Strong Biomarker [125]
HDLBP OTKDEEYX Strong Biomarker [126]
HFM1 OTHV3EFE Strong Genetic Variation [127]
HLA-C OTV38BUJ Strong Biomarker [128]
HLA-DOA OTZE5Q7R Strong Biomarker [129]
HLA-DPB1 OTW8JHU2 Strong Genetic Variation [130]
HLA-DQA2 OT1DH0N9 Strong Genetic Variation [131]
HLA-DQB1 OTVVI3UI Strong Biomarker [132]
HLA-DRB4 OTNXIHQU Strong Genetic Variation [133]
HSPA2 OTSDET7B Strong Genetic Variation [134]
IARS1 OT9WXH5N Strong Altered Expression [50]
IL3 OT0CQ35N Strong Genetic Variation [135]
IL36A OTHBEL5H Strong Biomarker [136]
INS-IGF2 OTZR74BO Strong Genetic Variation [137]
INSL3 OT7KUNTE Strong Biomarker [100]
ISG20 OTCWRJJW Strong Biomarker [41]
ITM2A OT590V63 Strong Altered Expression [138]
IYD OT8BQWTE Strong Altered Expression [139]
JAKMIP2 OT2H3MRD Strong Genetic Variation [140]
JSRP1 OT1AAYWO Strong Genetic Variation [126]
KIR3DL1 OTPOSXFX Strong Biomarker [46]
KLK11 OT5PKX7Y Strong Biomarker [141]
LACRT OTROSU7Z Strong Biomarker [142]
LAD1 OT6YGTVX Strong Genetic Variation [143]
LMOD1 OTZ2MEMG Strong Biomarker [144]
LPP OT6TU8SE Strong Genetic Variation [68]
MAGI3 OTDJ5QUH Strong Biomarker [145]
MMP20 OT16S5S3 Strong Genetic Variation [146]
MT1B OTUA4FFH Strong Biomarker [50]
MT1E OTXJKU4Y Strong Biomarker [50]
MT1F OTZVUYG1 Strong Biomarker [50]
MT1G OTAV1OCR Strong Biomarker [50]
MT1H OT0MVBM6 Strong Biomarker [50]
MT1M OTVT8PLU Strong Biomarker [50]
MT1X OT9AKFVS Strong Biomarker [50]
NCR3 OT20M764 Strong Biomarker [46]
NDN OTYBYJ82 Strong Biomarker [147]
NELFE OTL4E94L Strong Genetic Variation [9]
NRXN3 OTJ0I7HJ Strong Genetic Variation [81]
NUDT10 OT61XMYC Strong Biomarker [148]
OR2AG1 OTEITRP4 Strong Genetic Variation [141]
PAX8 OTRPD9MI Strong Genetic Variation [149]
PDLIM7 OTAZVODU Strong Altered Expression [150]
PHLDB2 OTDKMB2G Strong Genetic Variation [78]
PRICKLE1 OT9HHEM9 Strong Genetic Variation [68]
PROK1 OT8S7RUG Strong Altered Expression [151]
PROK2 OT70IFEZ Strong Biomarker [151]
PRR3 OTCWSM5T Strong Biomarker [92]
PSMA6 OTJ6RPX5 Strong Genetic Variation [152]
PSORS1C1 OT9HK436 Strong Genetic Variation [78]
PTPN12 OT5WA666 Strong Biomarker [153]
PTPN21 OTQBZWSE Strong Biomarker [154]
RGS9 OTRA1LOC Strong Genetic Variation [146]
RNH1 OT6EC79B Strong Biomarker [123]
RPL17 OTTYMPS6 Strong Biomarker [155]
SCGB3A2 OTB63PHR Strong Biomarker [156]
SDF4 OTQ7WFYW Strong Biomarker [104]
SEL1L OTC0FB7T Strong Biomarker [157]
SERPINA7 OTUYVTSU Strong Biomarker [158]
SETD1A OTVVWRIC Strong Altered Expression [159]
SFXN1 OTL66767 Strong Genetic Variation [141]
SH2B2 OTEDHHDH Strong Biomarker [148]
SH2D1A OTLU49I5 Strong Genetic Variation [160]
SHC3 OT305NPA Strong Biomarker [123]
SIGLEC1 OTNWSQA9 Strong Altered Expression [161]
SLA OTV17DY2 Strong Genetic Variation [10]
SNX2 OT889MQA Strong Biomarker [162]
SS18L1 OT9ZEGV7 Strong Biomarker [27]
ST3GAL1 OTFCO8QX Strong Altered Expression [163]
STK26 OTW4QE0D Strong Altered Expression [164]
SUV39H2 OTU0F4LL Strong Altered Expression [159]
TAB2 OTPZK76F Strong Biomarker [165]
TAS2R38 OTX5MM36 Strong Biomarker [100]
TBXT OTHCO2F0 Strong Altered Expression [166]
TCF19 OT7NKLF9 Strong Genetic Variation [9]
TLR10 OTQ1KVJO Strong Genetic Variation [58]
TRAF4 OTJLRVMC Strong Biomarker [167]
TSBP1 OT5GE8IO Strong Genetic Variation [9]
TSHZ1 OTYQ9ECW Strong Genetic Variation [168]
FNDC5 OT5CSK9X Definitive Altered Expression [169]
------------------------------------------------------------------------------------
⏷ Show the Full List of 147 DOT(s)

References

1 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease. Eur Thyroid J. 2022 Jan 1;11(1):e210073.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
6 Associations of secreted phosphoprotein 1 and B lymphocyte kinase gene polymorphisms with autoimmune thyroid disease.Eur J Clin Invest. 2019 Mar;49(3):e13065. doi: 10.1111/eci.13065. Epub 2019 Jan 16.
7 Fine mapping MHC associations in Graves' disease and its clinical subtypes in Han Chinese.J Med Genet. 2018 Oct;55(10):685-692. doi: 10.1136/jmedgenet-2017-105146. Epub 2018 Jul 9.
8 Polymorphisms of IKZF3 Gene and Autoimmune Thyroid Diseases: Associated with Graves' Disease but Not with Hashimoto's Thyroiditis.Cell Physiol Biochem. 2018;45(5):1787-1796. doi: 10.1159/000487870. Epub 2018 Feb 28.
9 Identification of independent risk loci for Graves' disease within the MHC in the Japanese population.J Hum Genet. 2011 Nov;56(11):772-8. doi: 10.1038/jhg.2011.99. Epub 2011 Sep 8.
10 Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis.Hum Mol Genet. 2013 Aug 15;22(16):3347-62. doi: 10.1093/hmg/ddt183. Epub 2013 Apr 23.
11 A NOVEL COMPOUND HETEROZYGOUS VARIANT OF SLC12A3 GENE IN A PEDIGREE WITH GITELMAN SYNDROME CO-EXISTENT WITH THYROID DYSFUNCTION.Endocr Pract. 2018 Oct 2;24(10):889-893. doi: 10.4158/EP-2018-0218. Epub 2018 Aug 7.
12 Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases.Front Immunol. 2019 Feb 20;10:261. doi: 10.3389/fimmu.2019.00261. eCollection 2019.
13 The expression and distribution of S-100 protein and CD 83 in thyroid tissues of autoimmune thyroid diseases.Cell Mol Immunol. 2004 Oct;1(5):378-82.
14 Polymorphisms of ST2-IL18R1-IL18RAP gene cluster: a new risk for autoimmune thyroid diseases.Int J Immunogenet. 2016 Feb;43(1):18-24. doi: 10.1111/iji.12240. Epub 2015 Nov 14.
15 Functional polymorphisms in TBX21 and HLX are associated with development and prognosis of Graves' disease.Autoimmunity. 2012 Mar;45(2):129-36. doi: 10.3109/08916934.2011.622013. Epub 2011 Oct 21.
16 Detection of anti-1-AR autoantibodies in heart failure by a cell-based competition ELISA.Circ Res. 2012 Aug 31;111(6):675-84. doi: 10.1161/CIRCRESAHA.112.272682. Epub 2012 Jul 18.
17 Toll-Like Receptors-2 and -4 in Graves' Disease-Key Players or Bystanders?.Int J Mol Sci. 2019 Sep 24;20(19):4732. doi: 10.3390/ijms20194732.
18 CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.Endocrine. 2017 Jan;55(1):186-199. doi: 10.1007/s12020-016-1096-1. Epub 2016 Sep 16.
19 CD34- Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF- Expression in CD34+ Fibroblasts and Fibrocytes.Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2615-2622. doi: 10.1167/iovs.18-23951.
20 Increases of CD80 and CD86 Expression on Peripheral Blood Cells and their Gene Polymorphisms in Autoimmune Thyroid Disease.Immunol Invest. 2020 Feb;49(1-2):191-203. doi: 10.1080/08820139.2019.1688343. Epub 2019 Nov 22.
21 Novel therapies for thyroid autoimmune diseases: An update.Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101366. doi: 10.1016/j.beem.2019.101366. Epub 2019 Nov 28.
22 MiR-346 regulates CD4CXCR5?T cells in the pathogenesis of Graves' disease.Endocrine. 2015 Aug;49(3):752-60. doi: 10.1007/s12020-015-0546-5. Epub 2015 Feb 11.
23 Genes that characterize T3-predominant Graves' thyroid tissues.Eur J Endocrinol. 2013 Jan 17;168(2):137-44. doi: 10.1530/EJE-12-0507. Print 2013 Feb.
24 Pooled genome wide association detects association upstream of FCRL3 with Graves' disease.BMC Genomics. 2016 Nov 18;17(1):939. doi: 10.1186/s12864-016-3276-z.
25 Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis.Autoimmunity. 2008 Mar;41(2):163-73. doi: 10.1080/08916930701727749.
26 Production of IL-10 and IL-12 in CD40 and interleukin 4-activated mononuclear cells from patients with Graves' disease.Cytokine. 2000 Jun;12(6):688-93. doi: 10.1006/cyto.1999.0659.
27 Autoantibodies to FK506 binding protein 12 (FKBP12) in autoimmune diseases.Autoimmunity. 1999;29(3):159-70. doi: 10.3109/08916939908998531.
28 Clinical and genetic characteristics of patients with autoimmune thyroid disease with anti-islet autoimmunity.Metabolism. 2011 Jun;60(6):761-6. doi: 10.1016/j.metabol.2010.07.025. Epub 2010 Sep 9.
29 IL-18 gene polymorphism confers susceptibility to the development of anti-GAD65 antibody in Graves' disease.Diabet Med. 2006 Feb;23(2):211-5. doi: 10.1111/j.1464-5491.2005.01734.x.
30 Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease.J Clin Endocrinol Metab. 1995 Jul;80(7):2112-7. doi: 10.1210/jcem.80.7.7608264.
31 RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.J Clin Lab Anal. 2018 Feb;32(2):e22258. doi: 10.1002/jcla.22258. Epub 2017 May 31.
32 Human fibrocytes express multiple antigens associated with autoimmune endocrine diseases.J Clin Endocrinol Metab. 2014 May;99(5):E796-803. doi: 10.1210/jc.2013-3072. Epub 2014 Feb 11.
33 Constitutive Changes in Circulating Follicular Helper T Cells and Their Subsets in Patients with Graves' Disease.J Immunol Res. 2018 Dec 24;2018:8972572. doi: 10.1155/2018/8972572. eCollection 2018.
34 The expression analysis of ICOS-L on activated T cells and immature dendritic cells as well as malignant B cells and Grave's-disease-derived thyroid tissues by two novel mAbs against human ICOS-L.Tissue Antigens. 2007 Jan;69(1):62-72. doi: 10.1111/j.1399-0039.2006.00706.x.
35 Association of interleukin-16 polymorphisms with graves' disease in a Taiwanese population.Chin J Physiol. 2014 Apr 30;57(2):69-75. doi: 10.4077/CJP.2014.BAB150.
36 Effect of IL-21 on the Balance of Th17 Cells/Treg Cells in the Pathogenesis of Graves' Disease.Endocr Res. 2019 Nov;44(4):138-147. doi: 10.1080/07435800.2019.1600535. Epub 2019 May 4.
37 Genetic association between IL-17F gene polymorphisms and the pathogenesis of Graves' Disease in the Han Chinese population.Gene. 2013 Jan 10;512(2):300-4. doi: 10.1016/j.gene.2012.10.021. Epub 2012 Oct 27.
38 Increased IL-21/IL-21R expression and its proinflammatory effects in autoimmune thyroid disease.Cytokine. 2015 Apr;72(2):160-5. doi: 10.1016/j.cyto.2014.11.005. Epub 2015 Jan 31.
39 Both interleukin-23A polymorphism and serum interlukin-23 expression are associated with Graves' disease risk.Cell Immunol. 2015 Mar;294(1):39-43. doi: 10.1016/j.cellimm.2015.01.015. Epub 2015 Feb 3.
40 Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.Thyroid. 2012 Jul;22(7):730-6. doi: 10.1089/thy.2012.0007. Epub 2012 Jun 4.
41 Effect of Halofuginone on the Pathogenesis of Autoimmune Thyroid Disease in Different Mice Models.Endocr Metab Immune Disord Drug Targets. 2017;17(2):141-148. doi: 10.2174/1871530317666170424101256.
42 Increased serum interleukin-37 (IL-37) levels correlate with oxidative stress parameters in Hashimoto's thyroiditis.J Endocrinol Invest. 2019 Feb;42(2):199-205. doi: 10.1007/s40618-018-0903-3. Epub 2018 May 23.
43 Disease association of the CD103 polymorphisms in Taiwan Chinese Graves' ophthalmopathy patients.Ophthalmology. 2010 Aug;117(8):1645-51. doi: 10.1016/j.ophtha.2009.12.037. Epub 2010 Apr 24.
44 Association of KCNJ2 Genetic Variants with Susceptibility to Thyrotoxic Periodic Paralysis in Patients with Graves' Disease.Exp Clin Endocrinol Diabetes. 2017 Feb;125(2):75-78. doi: 10.1055/s-0042-119527. Epub 2016 Dec 22.
45 Polymorphism of killer cell immunoglobulin-like receptors (KIR) and their HLA ligands in Graves' disease.Mol Biol Rep. 2014 Aug;41(8):5367-74. doi: 10.1007/s11033-014-3408-y. Epub 2014 May 23.
46 NKG2A expression and impaired function of NK cells in patients with new onset of Graves' disease.Int Immunopharmacol. 2015 Jan;24(1):133-9. doi: 10.1016/j.intimp.2014.09.020. Epub 2014 Oct 1.
47 Immunoglobulin heavy chain variable region genes contribute to the induction of thyroid-stimulating antibodies in recombinant inbred mice.Genes Immun. 2010 Apr;11(3):254-63. doi: 10.1038/gene.2010.8.
48 Association of TNF-alpha, TNF-beta, IFN-gamma and IL-1Ra gene polymorphisms with Graves' disease in the Thai population.Asian Pac J Allergy Immunol. 2006 Dec;24(4):207-11.
49 Association of polymorphism of LTalpha and TNF genes with Graves' disease.Folia Histochem Cytobiol. 2001;39 Suppl 2:77-8.
50 Expression of Metallothionein I/II and Ki-67 Antigen in Graves' Disease.Anticancer Res. 2018 Dec;38(12):6847-6853. doi: 10.21873/anticanres.13059.
51 Identification of a novel staining pattern of bile duct epithelial cells in primary sclerosing cholangitis.Inflamm Bowel Dis. 2010 Feb;16(2):305-11. doi: 10.1002/ibd.21050.
52 High levels of DNA polymerase mRNA corresponding with the high activity in Graves' thyroid tissue.J Endocrinol Invest. 2017 Apr;40(4):385-389. doi: 10.1007/s40618-016-0571-0. Epub 2016 Nov 15.
53 MANAGEMENT OF THYROTOXICOSIS: PRECONCEPTION, PREGNANCY, AND THE POSTPARTUM PERIOD.Endocr Pract. 2019 Jan;25(1):62-68. doi: 10.4158/EP-2018-0356. Epub 2018 Oct 5.
54 Polymorphism in the transmembrane region of the major histocompatibility complex class I chain-related gene A: association of five GCT repetitions with Graves' disease in children.Thyroid. 2003 Sep;13(9):839-43. doi: 10.1089/105072503322401023.
55 L-selectin gene polymorphisms in Graves' disease.Clin Endocrinol (Oxf). 2007 Jul;67(1):145-51. doi: 10.1111/j.1365-2265.2007.02852.x. Epub 2007 Apr 25.
56 Screening of SLC26A4 gene in autoimmune thyroid diseases.Int J Immunogenet. 2013 Aug;40(4):284-91. doi: 10.1111/iji.12035. Epub 2012 Dec 22.
57 Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease.Endocrine. 2019 Apr;64(1):48-54. doi: 10.1007/s12020-019-01852-w. Epub 2019 Feb 19.
58 Polymorphisms in TLR1, TLR6 and TLR10 genes and the risk of Graves' disease.Autoimmunity. 2015 Feb;48(1):13-8. doi: 10.3109/08916934.2014.939269. Epub 2014 Jul 16.
59 Polymorphisms and expression of toll-like receptors in autoimmune thyroid diseases.Autoimmunity. 2017 May;50(3):182-191. doi: 10.1080/08916934.2016.1261835. Epub 2016 Dec 26.
60 The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families.Clin Endocrinol (Oxf). 2002 Jul;57(1):81-8. doi: 10.1046/j.1365-2265.2002.01566.x.
61 Analysis of BAFF gene polymorphisms in UK Graves' disease patients.Clin Endocrinol (Oxf). 2019 Jan;90(1):170-174. doi: 10.1111/cen.13872. Epub 2018 Nov 5.
62 Changes in thyroid function in euthyroid subjects with a family history of Graves' disease: a follow-up study of 69 patients.J Clin Endocrinol Metab. 1980 Nov;51(5):1123-7. doi: 10.1210/jcem-51-5-1123.
63 Myeloid related proteins are up-regulated in autoimmune thyroid diseases and activate toll-like receptor 4 and pro-inflammatory cytokines in vitro.Int Immunopharmacol. 2018 Jun;59:217-226. doi: 10.1016/j.intimp.2018.04.009. Epub 2018 Apr 13.
64 Identification of a Hashimoto thyroiditis susceptibility locus via a genome-wide comparison with Graves' disease.J Clin Endocrinol Metab. 2015 Feb;100(2):E319-24. doi: 10.1210/jc.2014-3431. Epub 2014 Nov 27.
65 Transcriptional regulation of the MHC II gene DRA in untransformed human thyrocytes.Int Immunol. 2000 Apr;12(4):405-13. doi: 10.1093/intimm/12.4.405.
66 A haplotype of the CYP27B1 promoter is associated with autoimmune Addison's disease but not with Graves' disease in a UK population.J Mol Endocrinol. 2005 Jun;34(3):859-63. doi: 10.1677/jme.1.01760.
67 The functional polymorphisms of VDR, GC and CYP2R1 are involved in the pathogenesis of autoimmune thyroid diseases.Clin Exp Immunol. 2014 Nov;178(2):262-9. doi: 10.1111/cei.12420.
68 Seven newly identified loci for autoimmune thyroid disease.Hum Mol Genet. 2012 Dec 1;21(23):5202-8. doi: 10.1093/hmg/dds357. Epub 2012 Aug 24.
69 Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease.J Biol Chem. 2011 Jul 8;286(27):24487-99. doi: 10.1074/jbc.M111.241166. Epub 2011 May 16.
70 Increased TTS abrogates IDO-mediated CD4(+) T cells suppression in patients with Graves' disease.Endocrine. 2009 Aug;36(1):119-25. doi: 10.1007/s12020-009-9184-0. Epub 2009 Apr 11.
71 Polymorphisms and expression of genes encoding Argonautes 1 and 2 in autoimmune thyroid diseases.Autoimmunity. 2018 Feb;51(1):35-42. doi: 10.1080/08916934.2017.1416468. Epub 2017 Dec 19.
72 Identification of BACH2 as a susceptibility gene for Graves' disease in the Chinese Han population based on a three-stage genome-wide association study.Hum Genet. 2014 May;133(5):661-71. doi: 10.1007/s00439-013-1404-2. Epub 2013 Dec 12.
73 Association Analysis of Single Nucleotide Polymorphisms in C1QTNF6, RAC2, and an Intergenic Region at 14q32.2 with Graves' Disease in Chinese Han Population.Genet Test Mol Biomarkers. 2017 Aug;21(8):479-484. doi: 10.1089/gtmb.2017.0009. Epub 2017 Jun 30.
74 Genetic association of Fc receptor-like glycoprotein with susceptibility to Graves' disease in a Chinese Han population.Immunobiology. 2016 Jan;221(1):56-62. doi: 10.1016/j.imbio.2015.08.002. Epub 2015 Aug 18.
75 Paediatric-onset and adult-onset Graves' disease share multiple genetic risk factors.Clin Endocrinol (Oxf). 2019 Feb;90(2):320-327. doi: 10.1111/cen.13887. Epub 2018 Nov 15.
76 Associations of gene polymorphisms in interferon-alpha signature-related genes with autoimmune thyroid diseases.Clin Endocrinol (Oxf). 2019 Dec;91(6):860-868. doi: 10.1111/cen.14090. Epub 2019 Sep 16.
77 The MAGI2 gene polymorphism rs2160322 is associated with Graves' disease but not with Hashimoto's thyroiditis.J Endocrinol Invest. 2019 Jul;42(7):843-850. doi: 10.1007/s40618-018-0990-1. Epub 2018 Dec 8.
78 Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study.Nat Commun. 2015 Jul 7;6:7633. doi: 10.1038/ncomms8633.
79 Autoimmune endocrine diseases.Minerva Endocrinol. 2018 Sep;43(3):305-322. doi: 10.23736/S0391-1977.17.02757-2. Epub 2017 Oct 9.
80 Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease.Clin Pharmacol Ther. 2017 Dec;102(6):1017-1024. doi: 10.1002/cpt.733. Epub 2017 Jul 10.
81 Fine mapping of loci linked to autoimmune thyroid disease identifies novel susceptibility genes.J Clin Endocrinol Metab. 2013 Jan;98(1):E144-52. doi: 10.1210/jc.2012-2408. Epub 2012 Nov 1.
82 Transcriptome study of differential expression in schizophrenia.Hum Mol Genet. 2013 Dec 15;22(24):5001-14. doi: 10.1093/hmg/ddt350. Epub 2013 Jul 30.
83 Genetic variants of BANK1 gene in autoimmune thyroid diseases: a case-control association study.Exp Clin Endocrinol Diabetes. 2013 Oct;121(9):556-60. doi: 10.1055/s-0033-1348220. Epub 2013 Oct 14.
84 Polymorphism of IL37 gene as a protective factor for autoimmune thyroid disease.J Mol Endocrinol. 2015 Dec;55(3):209-18. doi: 10.1530/JME-15-0144. Epub 2015 Sep 15.
85 Expression Profile of Human Fc Receptor-Like 1, 2, and 4 Molecules in Peripheral Blood Mononuclear Cells of Patients with Hashimoto's Thyroiditis and Graves' Disease.Horm Metab Res. 2015 Aug;47(9):693-8. doi: 10.1055/s-0035-1545280. Epub 2015 Mar 4.
86 A novel FoxD3 Variant Is Associated With Vitiligo and Elevated Thyroid Auto-Antibodies.J Clin Endocrinol Metab. 2015 Oct;100(10):E1335-42. doi: 10.1210/jc.2015-2126. Epub 2015 Aug 12.
87 PVU II polymorphism of LST-1 (leucocyte specific transcript-1) in type I diabetes mellitus, Graves' disease and healthy controls.Eur J Immunogenet. 1995 Jun;22(3):277-82. doi: 10.1111/j.1744-313x.1995.tb00242.x.
88 Association of interleukin-17A and -17F gene single-nucleotide polymorphisms with autoimmune thyroid diseases.Autoimmunity. 2012 Nov;45(7):533-9. doi: 10.3109/08916934.2012.702814. Epub 2012 Aug 17.
89 Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders.J Intern Med. 1999 Mar;245(3):277-86. doi: 10.1046/j.1365-2796.1999.0443f.x.
90 No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves' disease.Clin Endocrinol (Oxf). 2005 Mar;62(3):362-5. doi: 10.1111/j.1365-2265.2005.02224.x.
91 Assessment of Molecular Subtypes in Thyrotoxic Periodic Paralysis and Graves Disease Among Chinese Han Adults: A Population-Based Genome-Wide Association Study.JAMA Netw Open. 2019 May 3;2(5):e193348. doi: 10.1001/jamanetworkopen.2019.3348.
92 Single nucleotide polymorphisms at the PRR3, ABCF1, and GNL1 genes in the HLA class I region are associated with Graves' ophthalmopathy in a gender-dependent manner.Ophthalmology. 2014 Oct;121(10):2033-9. doi: 10.1016/j.ophtha.2014.04.027. Epub 2014 Jun 5.
93 AIRE genetic variants and predisposition to polygenic autoimmune disease: The case of Graves' disease and a systematic literature review.Hum Immunol. 2016 Aug;77(8):643-651. doi: 10.1016/j.humimm.2016.06.002. Epub 2016 Jun 4.
94 Decreased circulating levels of ANGPTL8 in Graves' disease patients.Hormones (Athens). 2019 Jun;18(2):189-195. doi: 10.1007/s42000-019-00095-8. Epub 2019 Mar 21.
95 Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.Nat Genet. 2012 Mar 25;44(5):511-6. doi: 10.1038/ng.2231.
96 Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.Thyroid. 2014 Jul;24(7):1156-61. doi: 10.1089/thy.2013.0654. Epub 2014 Jun 3.
97 Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74.Clin Endocrinol (Oxf). 2006 Oct;65(4):429-32. doi: 10.1111/j.1365-2265.2006.02586.x.
98 Polymorphism of the second component of complement (C2) in Graves' disease.Hum Hered. 1980;30(4):245-7. doi: 10.1159/000153136.
99 C4A gene deletion: association with Graves' disease.J Mol Endocrinol. 1989 Sep;3(2):145-53. doi: 10.1677/jme.0.0030145.
100 INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes.Int J Oncol. 2003 May;22(5):993-1001.
101 Polymorphisms of DNA base-excision repair genes APE/Ref-1 and XRCC1 are not associated with the risk for Graves' disease.Cell Biochem Funct. 2009 Oct;27(7):462-7. doi: 10.1002/cbf.1595.
102 CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis.Hum Immunol. 2013 Feb;74(2):249-55. doi: 10.1016/j.humimm.2012.10.009. Epub 2012 Oct 13.
103 CEP128 is a crucial risk locus for autoimmune thyroid diseases.Mol Cell Endocrinol. 2019 Jan 15;480:97-106. doi: 10.1016/j.mce.2018.10.017. Epub 2018 Oct 27.
104 A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin.Autoimmunity. 1999;29(1):1-9. doi: 10.3109/08916939908995967.
105 The associations between the polymorphisms in the CTLA-4 gene and the risk of Graves' disease in the Chinese population.BMC Med Genet. 2013 Apr 19;14:46. doi: 10.1186/1471-2350-14-46.
106 Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study.Exp Clin Endocrinol Diabetes. 2006 Jun;114(6):329-35. doi: 10.1055/s-2006-924256.
107 Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).Clin Exp Immunol. 1997 Sep;109(3):495-500. doi: 10.1046/j.1365-2249.1997.4781381.x.
108 Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.J Immunol. 2003 Jun 15;170(12):6348-54. doi: 10.4049/jimmunol.170.12.6348.
109 Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy.Clin Exp Med. 2019 May;19(2):245-254. doi: 10.1007/s10238-018-00542-7. Epub 2019 Jan 4.
110 Screening of SNPs at 18 positional candidate genes, located within the GD-1 locus on chromosome 14q23-q32, for susceptibility to Graves' disease: a TDT study.Mol Genet Metab. 2004 Nov;83(3):264-70. doi: 10.1016/j.ymgme.2004.07.011.
111 DICER and DROSHA gene expression and polymorphisms in autoimmune thyroid diseases.Autoimmunity. 2016 Dec;49(8):514-522. doi: 10.1080/08916934.2016.1230846. Epub 2016 Nov 3.
112 Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease.J Clin Endocrinol Metab. 2018 Oct 1;103(10):3668-3677. doi: 10.1210/jc.2018-00509.
113 No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies.Clin Endocrinol (Oxf). 1998 Sep;49(3):331-4. doi: 10.1046/j.1365-2265.1998.00542.x.
114 T-cell recognition of residue 158-176 in thyrotropin receptor confers risk for development of thyroid autoimmunity in siblings in a family with Graves' disease.Thyroid. 1996 Dec;6(6):545-51. doi: 10.1089/thy.1996.6.545.
115 (99)Tc(m)-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy.Eye (Lond). 2017 May;31(5):668-676. doi: 10.1038/eye.2017.42. Epub 2017 Apr 7.
116 Mean peak systolic velocity of superior thyroid artery for the differential diagnosis of thyrotoxicosis: a diagnostic meta-analysis.BMC Endocr Disord. 2019 Jun 6;19(1):56. doi: 10.1186/s12902-019-0388-x.
117 Decreased expression of FcRII in active Graves' disease patients.J Clin Lab Anal. 2019 Jul;33(6):e22904. doi: 10.1002/jcla.22904. Epub 2019 Apr 29.
118 A refined study of FCRL genes from a genome-wide association study for Graves' disease.PLoS One. 2013;8(3):e57758. doi: 10.1371/journal.pone.0057758. Epub 2013 Mar 7.
119 Autoimmunity involving the human sodium/iodide symporter: fact or fiction?.Exp Clin Endocrinol Diabetes. 2001;109(1):35-40. doi: 10.1055/s-2001-11011.
120 Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases.PLoS Genet. 2011 Aug;7(8):e1002216. doi: 10.1371/journal.pgen.1002216. Epub 2011 Aug 4.
121 Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma.Cancer Biomark. 2010-2011;8(1):43-51. doi: 10.3233/DMA-2011-0824.
122 Evidence for a new Graves disease susceptibility locus at chromosome 18q21.Am J Hum Genet. 2000 May;66(5):1710-4. doi: 10.1086/302908. Epub 2000 Apr 3.
123 Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26.
124 CD40 Signaling in Graves Disease Is Mediated Through Canonical and Noncanonical Thyroidal Nuclear Factor B Activation.Endocrinology. 2017 Feb 1;158(2):410-418. doi: 10.1210/en.2016-1609.
125 Differentiation of autoimmune ophthalmopathy from Graves' hyperthyroidism by analysis of genetic markers.Clin Endocrinol (Oxf). 1988 Jun;28(6):601-10. doi: 10.1111/j.1365-2265.1988.tb03851.x.
126 Follow-up of potential novel Graves' disease susceptibility loci, identified in the UK WTCCC genome-wide nonsynonymous SNP study.Eur J Hum Genet. 2010 Sep;18(9):1021-6. doi: 10.1038/ejhg.2010.55. Epub 2010 May 5.
127 The A946T polymorphism in the interferon induced helicase gene does not confer susceptibility to Graves' disease in Chinese population.Endocrine. 2007 Oct;32(2):143-7. doi: 10.1007/s12020-007-9024-z. Epub 2007 Nov 17.
128 Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients.Biomed Pharmacother. 2019 Sep;117:109095. doi: 10.1016/j.biopha.2019.109095. Epub 2019 Jun 12.
129 Low expression and secretion of circulating soluble CTLA-4 in peripheral blood mononuclear cells and sera from type 1 diabetic children.Diabetes Metab Res Rev. 2012 Jan;28(1):84-96. doi: 10.1002/dmrr.1286.
130 Construction of a population-specific HLA imputation reference panel and its application to Graves' disease risk in Japanese.Nat Genet. 2015 Jul;47(7):798-802. doi: 10.1038/ng.3310. Epub 2015 Jun 1.
131 HLA-DQ haplotypes in Spanish and German families with Graves' disease: contribution to DQA1*0501-DQB1*0301 mediated genetic susceptibility from fathers.Thyroid. 2007 Nov;17(11):1131-5. doi: 10.1089/thy.2006.0315.
132 Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' disease.Genes Immun. 2008 Jun;9(4):358-63. doi: 10.1038/gene.2008.26. Epub 2008 May 1.
133 HLA-DRB3*0101 is associated with Graves' disease in Jamaicans.Clin Endocrinol (Oxf). 2001 Dec;55(6):805-8. doi: 10.1046/j.1365-2265.2001.01414.x.
134 Heat shock protein 70 polymorphisms in Chinese patients with Graves' disease.Genet Mol Res. 2015 Dec 28;14(4):18376-83. doi: 10.4238/2015.December.23.25.
135 Confirmation of association of chromosome 5q31-33 with United Kingdom Caucasian Graves' disease.Thyroid. 2010 Apr;20(4):413-7. doi: 10.1089/thy.2009.0375.
136 Elevated Interleukin-36 And CD4(+)IL-36(+)T Cells Are Involved in the Pathogenesis of Graves' Disease.Front Endocrinol (Lausanne). 2018 Oct 9;9:591. doi: 10.3389/fendo.2018.00591. eCollection 2018.
137 Evidence for a Type 1 diabetes-specific mechanism for the insulin gene-associated IDDM2 locus rather than a general influence on autoimmunity.Diabet Med. 2004 Mar;21(3):267-70. doi: 10.1111/j.1464-5491.2004.01129.x.
138 ITM2A Expands Evidence for Genetic and Environmental Interaction in Graves Disease Pathogenesis.J Clin Endocrinol Metab. 2017 Feb 1;102(2):652-660. doi: 10.1210/jc.2016-2625.
139 Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
140 Linkage Analysis of the Chromosome 5q31-33 Region Identifies JAKMIP2 as a Risk Factor for Graves' Disease in the Chinese Han Population.Med Sci Monit. 2019 Feb 23;25:1439-1451. doi: 10.12659/MSM.911489.
141 Thymic stromal lymphopoietin gene promoter polymorphisms and expression levels in Graves' disease and Graves' ophthalmopathy.BMC Med Genet. 2012 Nov 30;13:116. doi: 10.1186/1471-2350-13-116.
142 Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.PLoS One. 2017 Apr 18;12(4):e0175274. doi: 10.1371/journal.pone.0175274. eCollection 2017.
143 The interferon-induced helicase C domain-containing protein 1 gene variant (rs1990760) as an autoimmune-based pathology susceptibility factor.Immunobiology. 2020 Jan;225(1):151864. doi: 10.1016/j.imbio.2019.10.013. Epub 2019 Nov 5.
144 Leiomodins: larger members of the tropomodulin (Tmod) gene family.Genomics. 2001 Apr 15;73(2):127-39. doi: 10.1006/geno.2000.6501.
145 The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves' disease.Clin Endocrinol (Oxf). 2015 Oct;83(4):556-62. doi: 10.1111/cen.12640. Epub 2014 Dec 22.
146 Thyrotropin receptor antibodies and a genetic hint in antithyroid drug-induced adverse drug reactions.Expert Opin Drug Saf. 2018 Aug;17(8):775-784. doi: 10.1080/14740338.2018.1502747. Epub 2018 Aug 1.
147 Accumulation of identical T cell clones in the right and left lobes of the thyroid gland in patients with Graves' disease: analysis of T cell clonotype in vivo.Endocr J. 2000 Apr;47(2):127-36. doi: 10.1507/endocrj.47.127.
148 HLA-DQA1*0301-associated susceptibility for autoimmune polyglandular syndrome type II and III.Horm Metab Res. 2003 Feb;35(2):120-4. doi: 10.1055/s-2003-39059.
149 Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies.Thyroid. 2005 Sep;15(9):997-1003. doi: 10.1089/thy.2005.15.997.
150 The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases.Endokrynol Pol. 2015;66(2):132-6. doi: 10.5603/EP.2015.0020.
151 Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.Thyroid. 2011 Apr;21(4):391-9. doi: 10.1089/thy.2010.0168.
152 Microsatellite genotyping of chromosome 14q13.2-14q13 in the vicinity of proteasomal gene PSMA6 and association with Graves' disease in the Latvian population.Immunogenetics. 2004 Jul;56(4):238-43. doi: 10.1007/s00251-004-0687-9. Epub 2004 Jun 17.
153 Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy.Clin Endocrinol (Oxf). 2007 Nov;67(5):663-7. doi: 10.1111/j.1365-2265.2007.02942.x. Epub 2007 Jul 3.
154 Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with Graves' disease.Clin Endocrinol (Oxf). 2006 Sep;65(3):380-4. doi: 10.1111/j.1365-2265.2006.02608.x.
155 Frequencies of PD-1- positive T CD3+CD4+, T CD3+CD8+ and BCD19+ lymphocytes in female patients with Graves' disease and healthy controls- preliminary study.Mol Cell Endocrinol. 2017 Jun 15;448:28-33. doi: 10.1016/j.mce.2017.03.006. Epub 2017 Mar 8.
156 Uterus globulin associated protein 1 (UGRP1) is a potential marker of progression of Graves' disease into hypothyroidism.Mol Cell Endocrinol. 2019 Aug 20;494:110492. doi: 10.1016/j.mce.2019.110492. Epub 2019 Jun 27.
157 SEL1L microsatellite polymorphism in Japanese patients with autoimmune thyroid diseases.Thyroid. 2001 Apr;11(4):335-8. doi: 10.1089/10507250152039064.
158 Graves' disease associated with familial deficiency of thyroxine-binding globulin.J Clin Endocrinol Metab. 1977 Feb;44(2):242-7. doi: 10.1210/jcem-44-2-242.
159 Aberrant Histone Methylation in Patients with Graves' Disease.Int J Endocrinol. 2019 Jun 24;2019:1454617. doi: 10.1155/2019/1454617. eCollection 2019.
160 General and Specific Genetic Polymorphism of Cytokines-Related Gene in AITD.Mediators Inflamm. 2017;2017:3916395. doi: 10.1155/2017/3916395. Epub 2017 Jan 4.
161 Sialic Acid-Binding Immunoglobulin-Like Lectin1 as a Novel Predictive Biomarker for Relapse in Graves' Disease: A Multicenter Study.Thyroid. 2018 Jan;28(1):50-59. doi: 10.1089/thy.2017.0244. Epub 2017 Nov 21.
162 Sorting Nexin 2 (SNX2): a potential marker of active thyrocytes in normal and hyperfunctioning thyroid disorders.Appl Immunohistochem Mol Morphol. 2014 Apr;22(4):302-7. doi: 10.1097/PAI.0b013e31828badd3.
163 Thyroid sialyltransferase mRNA level and activity are increased in Graves' disease.Thyroid. 2005 Jul;15(7):645-52. doi: 10.1089/thy.2005.15.645.
164 MST-4 and TRAF-6 expression in the peripheral blood mononuclear cells of patients with Graves' disease and its significance.BMC Endocr Disord. 2017 Feb 20;17(1):11. doi: 10.1186/s12902-017-0161-y.
165 Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease.J Clin Endocrinol Metab. 2006 Mar;91(3):1056-61. doi: 10.1210/jc.2005-1634. Epub 2005 Dec 29.
166 Thyrotoxic crisis as an acute clinical presentation in a child.BMJ Case Rep. 2018 Mar 23;2018:bcr2017222850. doi: 10.1136/bcr-2017-222850.
167 MicroRNA-4443 Causes CD4+ T Cells Dysfunction by Targeting TNFR-Associated Factor 4 in Graves' Disease.Front Immunol. 2017 Nov 1;8:1440. doi: 10.3389/fimmu.2017.01440. eCollection 2017.
168 Foxp3 gene polymorphisms and haplotypes associate with susceptibility of Graves' disease in Chinese Han population.Int Immunopharmacol. 2015 Apr;25(2):425-31. doi: 10.1016/j.intimp.2015.02.020. Epub 2015 Feb 21.
169 The association between irisin and muscle metabolism in different thyroid disorders.Clin Endocrinol (Oxf). 2018 Mar;88(3):460-467. doi: 10.1111/cen.13527. Epub 2017 Dec 20.